Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Non-Current Liabilities: 2013-2024

Historic Total Non-Current Liabilities for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $144.1 million.

  • Fortress Biotech's Total Non-Current Liabilities fell 16.99% to $114.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year decrease of 16.99%. This contributed to the annual value of $144.1 million for FY2024, which is 12.15% down from last year.
  • Per Fortress Biotech's latest filing, its Total Non-Current Liabilities stood at $144.1 million for FY2024, which was down 12.15% from $164.0 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Total Non-Current Liabilities ranged from a high of $242.4 million in FY2022 and a low of $134.5 million during FY2020.
  • For the 3-year period, Fortress Biotech's Total Non-Current Liabilities averaged around $183.5 million, with its median value being $164.0 million (2023).
  • As far as peak fluctuations go, Fortress Biotech's Total Non-Current Liabilities soared by 43.80% in 2022, and later plummeted by 32.33% in 2023.
  • Yearly analysis of 5 years shows Fortress Biotech's Total Non-Current Liabilities stood at $134.5 million in 2020, then rose by 25.38% to $168.6 million in 2021, then surged by 43.80% to $242.4 million in 2022, then crashed by 32.33% to $164.0 million in 2023, then fell by 12.15% to $144.1 million in 2024.